Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells.
Teh CE, Peng H, Luo MX, Tan T, Trussart M, Howson LJ, Chua CC, Muttiah C, Brown F, Ritchie ME, Wei AH, Roberts AW, Bryant VL, Anderson MA, Lindeman GJ, Huang DCS, Thijssen R, Gray DHD.
Teh CE, et al. Among authors: roberts aw.
Blood Adv. 2023 Jun 27;7(12):2733-2745. doi: 10.1182/bloodadvances.2022008221.
Blood Adv. 2023.
PMID: 36521105
Free PMC article.